Matrilin-3 pretreated autologous adipose-derived mesenchymal stem cells implantation
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Matrilin-3 pretreated autologous adipose-derived mesenchymal stem cells implantation, covering 2021-08-25 to 2021-08-25. Get the full timeline:
Most recent: Clinical Trial Update: Safety and Efficacy Study of Matrilin-3 Pretreated Autologous Adipose Derived Mesenchymal Stem Cells Implantation in Chronic Low Back Pain Patients With Lumbar Intervertebral Disc Degeneration [Phase 1, Phase 2]